2009 Annual Meeting | Neuromuscular Therapy

Date Thursday 04/30/09

Time 07:00 PM - 09:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Therapy Program

Director(s) Robert C. Griggs, MD, FAAN

Topic(s)

Learning Objectives Participants should have perspective on current and future treatments for neuromuscular disease.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
07:00 PM - 07:30 PM		Neuromuscular Junction Disorders Carlayne E. Jackson, MD, FAAN
07:00 PM - 09:00 PM		Reception
07:30 PM - 07:40 PM		Discussion
07:40 PM - 08:10 PM		Peripheral Neuropathies Richard J. Barohn, MD, FAAN
08:10 PM - 08:20 PM		Discussion
08:20 PM - 08:50 PM		Muscle Disease Robert C. Griggs, MD, FAAN
08:50 PM - 09:00 PM		Discussion

Faculty Disclosures
Richard J. Barohn, MD, FAAN	Dr. Barohn has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for NuFactor. The institution of Dr. Barohn has received research support from FDA OPD R01. Dr. Barohn has received intellectual property interests from a discovery or technology relating to health care.
Robert C. Griggs, MD, FAAN	Dr. Griggs has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Strongbridge Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idera Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Solid Biopharma. Dr. Griggs has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Santhera Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Lippincott. The institution of Dr. Griggs has received research support from PTC Pharmaceuticals. The institution of Dr. Griggs has received research support from Sarepta Pharmaceuticals. The institution of Dr. Griggs has received research support from National Institutes of Health. The institution of Dr. Griggs has received research support from Santhere Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as a Study section member with National Institutes of Health. Dr. Griggs has a non-compensated relationship as a Board of Directors;Chair Research Advisory Committee with American Brain Foundation that is relevant to AAN interests or activities.
Carlayne E. Jackson, MD, FAAN	Dr. Jackson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe Pharma America. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN. The institution of Dr. Jackson has received research support from NIH. The institution of Dr. Jackson has received research support from Massachussetts General Hospital.

��ɫ��

��ɫ��